STAT+: Unexpected troubles hit large medical billing firm R1 RCM, part-owned by Ascension
The stock price of R1 RCM tanked by roughly 50% this week after the large…
Category: STAT+
STAT+: Unexpected troubles hit large medical billing firm R1 RCM, part-owned by Ascension
The stock price of R1 RCM tanked by roughly 50% this week after the large…
STAT+: Telehealth companies that prescribed controlled substances during the pandemic brace for business to change
Health tech companies that have taken advantage of the possibility to prescribe controlled substances online…
STAT+: Biogen’s new CEO, clear-eyed about company’s challenges, prepares to take the reins
Christopher Viehbacher, who will start as Biogen’s CEO on Monday, knows that running Biogen may…
STAT+: Viatris executive is charged with insider trading scheme involving a friend and former colleague
A high-ranking Viatris executive was charged with insider trading for tipping a friend and former…
STAT+: PACT Pharma’s personalized cancer treatments, powered by CRISPR, clear early safety hurdles
Two years ago, researchers at the University of Pennsylvania showed for the first time that…
STAT+: Pharmalittle: Biogen hires Viehbacher as its CEO; new dengue vaccine rolled out amid safety concerns
Top of the morning to you, and a fine one it is. Crystal clear blue…
STAT+: Biogen appoints former Sanofi executive Christopher Viehbacher as CEO
Biogen named Christopher Viehbacher, who formerly ran the French drug giant Sanofi, as its new…
STAT+: Seagen names longtime Novartis exec as new CEO
Seagen announced Thursday that it had hired a new CEO, naming pharmaceutical industry executive David…
STAT+: For its first two medicines, EQRx abandons its bold strategy to lower drug prices
Changing the way cancer drugs are priced in the U.S. is apparently even harder than…
STAT+: Jeff Jonas leaves Sage Therapeutics to launch biotech incubator
Longtime Sage Therapeutics executive Jeff Jonas is leaving the biotech company to launch a biotech…
STAT+: FDA panel votes against Veru’s drug for severe Covid
An FDA advisory panel voted 5-to-8 to recommend rejecting a new drug for patients hospitalized…
STAT+: Clovis Oncology warns of likely bankruptcy filing following years of scandal and financial losses
Clovis Oncology, a maker of cancer drugs, warned Wednesday that it will likely file for…
STAT+: Pharmalittle: ADC backs off accelerated approval after FDA demands confirmatory trial; explaining the Supreme Court’s split on drug-patent cases
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Shares of Merrimack, a dormant drugmaker, soar after cancer drug succeeds in trial
Shares of Merrimack Pharmaceuticals, a shuttered drug company with no employees or any active research…
STAT+: Andreessen Horowitz partners with rural health system to give its companies a go-to pilot site
Innovative health tech startups with big ideas will not get very far if they cannot…
STAT+: Faze Medicines, a biotech focused on neurological diseases, is shutting down
A biotech company that hoped to use cell biology to address neurological disorders is shutting…
STAT+: The U.S. Supreme Court will review a contentious Amgen patent case, but not one involving Bristol. Why?
In a surprising move, the U.S. Supreme Court rejected a bid by a Bristol Myers…
STAT+: Talkspace names a new CEO as its stock price continues to struggle
Following a year of executive shakeups and business rejiggering, Talkspace’s third quarter earnings came with…
STAT+: Pharmalittle: Biogen mulls new options in its CEO hunt; NIH starts contacting universities about overdue trial results
Rise and shine, everyone, another busy day is on the way. This is especially true…
STAT+: After years of lax oversight, the NIH is starting to contact institutions about unreported clinical trial results
In recent weeks, the U.S. National Institutes of Health has begun emailing academic institutions that…
STAT+: J&J’s Mammen out of the running for Biogen CEO post
Biogen is mulling new options in its search for a CEO after talks with a…
STAT+: Amid concerns over U.S. democracy, pharma helped finance committees that support election deniers
As Americans head to the polls, some candidates continue to deny the results of the…
STAT+: Pharmalittle: Some Lilly workers want transfers due to Indiana abortion law; GSK cancer drug flops in late-stage study
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FDA places clinical hold on Verve Therapeutics gene-edting treatment
Verve Therapeutics said Monday that its experimental gene-editing treatment for a common form of heart…
STAT+: Microsoft’s note-taking tool asks doctors to make a grand bargain: Share patient data, and get your life back
The artificial intelligence system is a dream for many doctors: It records their conversations with…
STAT+: Muscular dystrophy patient who was first in line for a custom CRISPR therapy dies
A man with muscular dystrophy who was first in line to receive an experimental gene…
STAT+: U.S. Supreme Court gives Amgen a boost by agreeing to review a closely watched patent case
In a boost for Amgen, the U.S. Supreme Court on Friday agreed to hear a…
STAT+: A ‘blank check’: Bill to boost antibiotic development blasted as a ‘flawed’ giveaway to pharma
Amid mounting concern over antibiotic resistance, a coalition of academics and advocacy groups is urging…
STAT+: Pharmalittle: Europe approves a Sanofi and AstraZeneca RSV shot; CDC updates opioid prescribing guidelines
And so, another working week will soon draw to a close. Not a moment too…
STAT+: FDA approval decision for Apellis Pharma’s eye disease drug delayed to review more clinical data
Apellis Pharmaceuticals said Thursday that submission of additional clinical data to the Food and Drug…
STAT+: A leaked version of a U.K.-India free trade deal sparks alarm over access to medicines
A leaked draft version of a trade agreement being negotiated between the United Kingdom and…
STAT+: Pharmalittle: Moderna must face patent claims over its Covid-19 vaccine; Pfizer and BioNTech testing combo Covid and flu shot
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: A live chat about ‘biology’s century’
CRISPR, gene therapy, CAR-T, and Covid vaccines. Science is advancing at a blistering pace. But…
Opinion: STAT+: HHS’s proposed rule prohibiting discrimination via algorithm needs strengthening
The Department of Health and Human Services has proposed a rule to prohibit clinical algorithms…
STAT+: Weight-loss drug had dramatic effect in adolescents with obesity, study finds
A blockbuster weight-loss medicine led to dramatic effects for adolescents diagnosed with obesity, a result…
STAT+: Medicare punts on quality rules for new type of rural hospital
Hospitals that decide to convert to a new type of rural provider won’t have to…
STAT+: Physicians rally to avert Medicare payment cuts
The federal government is officially reducing Medicare payments to physicians next year by 4.5%, but…
STAT+: Novel solution to biotech’s market valuation woes: Just give the cash back
It’s tough times to be a public biotech, especially a small one. As the market…
STAT+: Biotech company seeks to overcome hurdles to develop flu vaccine skin patch
In the future, getting a flu shot might be as easy as opening the mailbox…
.jpg)
STAT+: A turnaround for Editas Medicine, a CRISPR laggard, hinges on updates on key treatments
Editas Medicine’s new leadership team on Wednesday reiterated a promise to deliver clinical updates on…
STAT+: Pharmalittle: FDA panel urges improved regulation of pulse oximeters; CVS Health agrees to $5 billion settlement over opioid lawsuits
Good morning from San Diego. I’m Jonathan Wosen, STAT’s West Coast biotech reporter, and I’m…
STAT+: Pharmalittle: Pfizer maternal RSV vaccine meets pivotal study’s goal; Lilly cuts its annual profit forecast
Tumble out of bed and stumble to the kitchen, pour myself a cup of ambition,…
.jpg)
Pfizer says vaccine to prevent RSV in newborns is effective
Pfizer’s maternal vaccine against the respiratory syncytial virus reduced the rate of severe illness in…
STAT+: Advanced practice clinicians slightly more likely to take industry funding than doctors
A slightly larger share of nurse practitioners, physician assistants, and other advanced practice clinicians accept…
STAT+: Pharmalittle: FDA advisers vote down pediatric brain cancer drug; AbbVie drops out of psoriasis partnership
Good morning, and welcome to a spooky edition of Pharmalittle. It’s Jason Mast here, filling…
STAT+: Private equity’s Welsh Carson, casting itself as a noble force, relentlessly pursues profits in health care
Before the allegations of neglect, before the lawsuits, before the government investigations, the health care…
STAT+: Pharmalittle: Drugmaker raises price of old chemo med 10-fold amid shortages; Alnylam cites drug-price law in halting trial
And so, another working week will soon draw to a close. Not a moment too…
STAT+: How experts think we can put health data back ‘in the hands of the patient’
Two decades ago, the Bush administration threw a wrench in health data privacy, making it…
Opinion: STAT+: The need for regulatory grade evidence: Are you in the stadium or the sandbox?
As real-world data (RWD) and real-world evidence (RWE) continue to share the limelight in pharmacoepidemiologic…